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ABSTRACT 
Objective: To study the in vitro dissolution performance of four generic formulations of the poorly soluble drug meloxicam and the reference under 
hydrodynamic environments generated by flow-through cell method and USP paddle apparatus (pharmacopeial test). 
Methods: Dissolution method was validated according to ICH guidelines. Dissolution profiles were carried out with an automated flow-through cell 
apparatus (laminar flow at 16 ml/min with 22.6 mm cells) and USP paddle apparatus at 75 rpm. Phosphate buffer pH 7.5 at 37.0±0.5 °C was used as 
dissolution medium. Spectrophotometric determination of drug at 362 nm was carried out during 30 min. Dissolution profiles were compared with 
model-dependent and-independent methods. 
Results: Practically, all generic formulations showed significant differences with the percentage of drug dissolved at 30 min, mean dissolution time 
and dissolution efficiency, when USP paddle apparatus was used (*P<0.05), while only two generic formulations were different to reference using 
flow-through cell method. After adjustment to different mathematical equations, Weibull function was the best model to describe meloxicam 
dissolution performance and significant differences were found with all drug products when USP paddle apparatus was used, while only one 
formulation was different with flow-through cell method. 
Conclusion: The study reveals the need to look for better dissolution schemes for meloxicam tablets since USP paddle apparatus may not reflect 
properly the in vitro dissolution performance of meloxicam generic formulations and reference. 
Keywords: Meloxicam, Flow-through cell method, Generic formulations, USP paddle apparatus 




Meloxicam is a member of enolic acid group of non-steroidal anti-
inflammatory drugs (NSAIDs) used to treat rheumatoid arthritis, 
osteoarthritis and other joint pains. The drug is practically insoluble 
in water (8 µg/ml) which directly influences the Cmax, Tmax and its 
bioavailability [1]. Meloxicam has pKa values of 1.1 and 4.2 and is 
considered a class II drug [2]. Class II drugs are expected to have a 
dissolution-limited absorption and significant in vitro/in vivo 
correlation should be projected using a well-designed in vitro 
dissolution test. Molecular structure of meloxicam is shown in fig. 1. 
 
 
Fig. 1: Molecular structure of meloxicam 
 
In vitro dissolution studies are not only used to assess batch-to-
batch consistency of drug release from solid dosage forms, but they 
are also essential in several stages of formulation development, for 
screening and proper assessment of different formulations [3]. Some 
methods have been proposed to compare dissolution profiles of 
reference and test formulations. FDA use f2 similarity factor [4] 
while model-dependent,-independent and ANOVA-base comparisons 
are the most commonly approaches used for a complete evaluation 
[5, 6]. 
Several authors have studied dissolution test optimization for 
meloxicam tablets [2] and the use of 900 ml phosphate buffer (pH 
7.5, 37.0±0.5 °C) with USP paddle apparatus (USP Apparatus 2) at 
100 rpm was considered satisfactory. Official dissolution test 
maintains similar conditions and only changes the agitation rate (75 
rpm) [7]. Pharmacopeial criteria establishes that not less than 70% 
of drug should be dissolved in 30 min (Q ≥ 70%). To date, there is no 
information confirming significant in vitro/in vivo correlation under 
these conditions. 
An alternative dissolution apparatus to determinate the release 
performance of drugs is the flow-through cell method (USP 
Apparatus 4) [8, 9]. Their advantages over conventional USP basket 
and paddle apparatus (USP Apparatus 1 and 2, respectively) have 
been widely demonstrated especially with poorly soluble drugs [10, 
11]. The flow-through cell method better simulates the 
hydrodynamic environment of the gastrointestinal tract. In vitro 
data obtained with USP Apparatus 4 better reflects the in vivo 
performance of some drugs with solubility problems [12, 13]. USP 
Apparatus 4 works as an open system that can operate under sink 
conditions and it is easy to change the dissolution medium (within a 
range of physiological pH) throughout the test [14]. Emara et al., 
[15] reported dissolution profiles of five meloxicam generic 
formulations and reference product (7.5-mg) obtained with flow-
through cell method (phosphate buffer pH 7.5 at 8 ml/min, laminar 
flow, and 22.6 mm cells). After several studies, three generic 
formulations showed less than 70% of drug dissolved at 30 min. 
Generic formulations are off-patent drug products that contain the 
same active ingredient in the same dose as the reference product 
[16]. These drug products represent saving for patients and 
hospitals and for its safe interchangeability, they must show the 
same quality as reference. However, some authors confirmed that 
during dissolution tests many generic formulations showed 
differences from their branded counterparts [17]. Some 
formulations showed incomplete dissolution and others showed that 
they dissolve slower or faster than their branded counterparts. 
Other generics, from the same manufacturer with different batches 
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of the same drug, showed significant differences suggesting that 
substitution among generics themselves can be risky. This is the case 
of meloxicam generic formulations (7.5 and 15-mg) when USP 
paddle apparatus at 50 rpm and 1000 ml of phosphate buffer pH 7.5 
was used [17]. 
The main objective in this in vitro dissolution behavior study is to 
evaluate the release performance of meloxicam from immediate-
release generic formulations sold in the local market. Due to its poor 
solubility, investigation of dissolution performance of this NSAID 
under the hydrodynamic environment generated by the flow-
through cell method is important. Data obtained were compared 
with the official USP paddle apparatus. Result could support the 
design of better drug products available for the population that uses 
them. 
MATERIALS AND METHODS 
Chemical and reagents 
Meloxicam tablets (15-mg) of the reference product Mobicox® 
(Boehringer Ingelheim) (coded as R product) and four generic 
formulations (A, B, C, and D products) with the same dose were 
used. Mexican health regulatory agency COFEPRIS has established 
Mobicox® as the reference product to be used in bioequivalence 
studies [18]. Hydrochloric acid and methanol analytical grade were 
purchased from J. T. Baker-Mexico (Xalostoc, Mexico). Meloxicam 
standard was purchased from Sigma-Aldrich Co. (St. Louis MO, USA). 
Content uniformity and assay 
Content uniformity and assay tests were carried out with all 
formulations according to the procedures described in the USP [7]. 
Analytical method validation 
Before the determination of dissolution profiles, dissolution method 
was validated according to ICH guidelines [19]. 
Linearity 
Three standard calibration curves in phosphate buffer pH 7.5 
(2.5-20 µg/ml, 362 nm) were prepared and data were fitted to the 
straight-line equation (y = bx+a). The coefficients of regression and 
regression analysis of variance (ANOVA) were calculated. The 
absorbance vs. meloxicam concentration proportionality was 
demonstrated by calculating the percentage relative standard 
deviation (RSD): [((standard deviation)/mean) × 100] of the 
response factor across the entire range of concentration. 
Accuracy and precision 
The accuracy and precision of the method were evaluated with the 
added standard method. With this method matrix, effects can easily 
be removed. Twenty tablets were accurately weighed and crushed in 
a mortar; then, quantities of powder of meloxicam tablets plus a 
quantity of meloxicam standard (10 mg) to finally give the 
equivalent of 80, 100, and 120% of the dose, were dissolved in 900 
ml of phosphate buffer pH 7.5 at 37.0±0.5 °C. USP paddle apparatus 
at 75 rpm was used. At 30 min the amount of meloxicam dissolved 
was calculated with reference to a standard calibration curve 
prepared on the same day of the experiment. Each determination 
was performed in triplicate. The percentage relative error (RE): 
[((found–added)/added) × 100] was taken as a measure of the 
accuracy and RSD as a measure of precision. Experiments were 
carried out in three different days. 
USP paddle apparatus 
Dissolution profiles of meloxicam were obtained using the 
dissolution test described in USP (USP 2018). USP Apparatus 2 
(Model AT-7 Smart, Sotax, Basel, Switzerland) at 75 rpm was used (Q 
= 70% at 30 min). The UV/Vis spectrophotometer (Model Lambda 
35, Perkin Elmer, USA) with 1 mm flow cells was used. Equipment 
was controlled by specific software designed by Sotax. Meloxicam 
tablets were sprinkled on 900 ml of phosphate buffer pH 7.5 at 
37.0±0.5 °C. Automatic samples were taken every 5 min to 30 min (n 
= 12). Meloxicam dissolved was determined with a standard 
calibration curve. 
Flow-through cell method 
Dissolution profiles of meloxicam were obtained with an USP 
Apparatus 4 (Model CE6, Sotax AG, Basel, Switzerland) and 22.6 mm 
cells (i.d.). Laminar flow (originated with 6 g of glass beads) at 16 
ml/min was tested. Phosphate buffer pH 7.5 at 37.0±0.5 °C was used 
as dissolution medium. Automatic samples were taken every 5 min 
up to 30 min (n = 12). Meloxicam dissolved was determined in an 
UV/Vis spectrophotometer (Model Lambda 10, Perkin Elmer, USA) 
with 1 mm cells at 362 nm. For every trial, a standard calibration 
curve was prepared. 
Dissolution data analysis 
Meloxicam dissolved at all sampling times, and not only data at 30 
min, from generic vs. reference formulations were compared. One-
way analysis of variance (ANOVA) followed by a Dunnett or 
Dunnett’s T3 multiple comparisons test was used. Significant 
differences were considered if *P<0.05. Dissolution data obtained 
with the flow-through cell method were compared by the same way. 
Dissolution profiles of reference and generic formulations were 
compared by model-independent and-dependent methods. For 
model-independent comparisons mean dissolution time (MDT) and 
dissolution efficiency (DE) were calculated. MDT is time to dissolve 
63.2% of drug and it was calculated according to statistical 
moment’s theory [20]. DE is the area under the dissolution curve up 
to a certain time, t, expressed as a percentage of the area of the 
rectangle described by 100% dissolution in the same time [21]. Both 
parameters were calculated with the Excel add-in DDSolver program 
[22]. For model-dependent comparisons dissolution data were 
adjusted to hyperbola equation (y = ax/b+x) and with a and b 
constants, t50%, t63.2%, and t85% values were calculated. This fit was 
carried out with SigmaPlot software (version 11.0).  
Additionally, and for a complete comparison of dissolution profiles 
by model-dependent approach, dissolution data were fitted to First-
order, Higuchi, Korsmeyer-Peppas, Hixson-Crowell, Makoid-
Banakar, Weibull, and Logistic equation. The model with the highest 
determination coefficient (R2adjusted) and minimum Akaike 
Information Criterion (AIC) was chosen as the best fit model [6]. 
Data analysis was carried out using Excel add-in DDSolver program 
[22]. Table 1 shows the mathematical equations of each model. 
 
Table 1: Mathematical models used to fit dissolution data of meloxicam formulations 
Model Equation 
Hyperbole  =  +  
First-order  = 100 ∙ 	1 − 1∙ 
Higuchi  =  ∙ 0.5 
Korsmeyer-Peppas  =  ∙  
Hixson-Crowell  = 100 ∙ 1 − 	1 −  ∙ 3 
Makoid-Banakar  =  ∙  ∙ ∙  
Weibull  =  ∙ 1 − 
	 !"#$
% & 
Logistic  = 100 ∙ 
'()∙*+,	
1 + '()∙*+,	 
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RESULTS AND DISCUSSION 
Content uniformity and assay 
Results of content uniformity and assay test made to meloxicam 
formulations are shown in table 2. All meloxicam formulations met 
the content uniformity and assay standard criteria. The percentages 
of meloxicam content ranged from 85 to 115% and the assay test 
was between 90 to 110%. 
Linearity 
Mean regression equation from three standard calibration curves 
was y = 0.0423x+0.0264. linear regression was significant (R2 = 
0.995, *P<0.05). The RSD value of response factor was 5.6%. 
Accuracy and precision 
To evaluate the accuracy and precision of the dissolution method, 
analysis of several percentages of dose (80, 100, and 120%) was 
carried out for three different days (n = 3/d). The within-run and 
between-run precision and accuracy were calculated. Results are 
shown in table 3. RSD obtained was in the range of 0.02-1.58% and 
RE was lower than 5.0% what indicates good accuracy and precision 
of the dissolution method. 
Dissolution performance 
Dissolution profiles of all meloxicam formulations, obtained with 
USP paddle apparatus and flow-through cell method, are shown in 
fig. 2. 
 
Table 2: Content uniformity and assay results of meloxicam formulations 
Code Content uniformity (min-max %) Assay (%) 
R 99.87-103.93 102.57 
A 100.58-109.04 106.54 
B 100.44-109.48 100.80 
C 103.36-108.61 101.58 
D 102.19-109.92 100.54 
 
Table 3: Accuracy and precision data of meloxicam, mean±SD 
 Within-day (n = 3) Between-day (n = 9) 
Added (mg) Found (mg) RSD (%) RE (%) Found (mg) RSD (%) RE (%) 
12 12.35±0.02 0.17 2.92 12.59±0.20 1.58 4.92 
15 15.35±0.00 0.02 2.35 15.47±0.14 0.91 3.13 
18 18.18±0.27 1.48 1.01 18.13±0.19 1.02 0.74 
RSD: Relative standard deviation; RE: Relative error 
 
 
Fig. 2: Dissolution profiles of meloxicam reference (R) and generic formulations (A-D). The dashed line shows Q = 70%. For clarity the 
error bars were omitted, mean, n = 12 
 
Under official conditions, all drug products met the pharmacopeial Q 
criterion (70% dissolved at 30 min). Results with USP Apparatus 4 
were similar excepting product A which less than 50% of meloxicam 
dissolved was found from this generic formulation. 
The rate and extent of meloxicam dissolved, from all formulations 
used and with USP Apparatus 4, was less than data obtained with 
USP paddle apparatus. Usually, with a flow-through cell method, it is 
possible to observe slower dissolution rates than those reported 
with USP basket or paddle apparatus [23, 24]. This performance can 
be explained by the hydrodynamic environment of USP Apparatus 4 
which better reflects the natural setting of the gastrointestinal tract 
than other USP dissolution apparatuses [25]. Cell size, glass beads 
and flow rate are critical factors to form a special dissolution pattern 
useful to compare the manufacture quality of generic formulations. 
Flow rate of 16 ml/min was used since it is one suggested by 
European and US Pharmacopeias (others are 4 and 8 ml/min) [26]. 
In order to compare the percentage of the drug found at each 
sampling time, of each generic formulation vs. reference, a one-way 
ANOVA followed by a Dunnett’s multiple comparison test was 
performed. Results are shown in table 4. 
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Table 4: Difference of meloxicam dissolved, at each sampling time, between generic formulations (A-D) and reference product (R) 
Comparison Time (min) USP paddle apparatus Flow-through cell method 
Difference *P Difference *P 
A vs. R 5 15.62 <0.05 6.43 <0.05 
 10 31.34 <0.05 18.45 <0.05 
 15 31.41 <0.05 26.82 <0.05 
 20 19.52 <0.05 30.11 <0.05 
 25 8.91 <0.05 29.53 <0.05 
 30 0.99 >0.05 27.07 <0.05 
B vs. R 5 9.41 <0.05 0.03 >0.05 
 10 21.29 <0.05 0.92 >0.05 
 15 26.24 <0.05 2.72 >0.05 
 20 27.70 <0.05 4.38 >0.05 
 25 27.84 <0.05 6.26 >0.05 
 30 27.69 <0.05 8.14 >0.05 
C vs. R 5 26.88 <0.05 0.37 >0.05 
 10 24.67 <0.05 0.11 >0.05 
 15 21.60 <0.05 0.78 >0.05 
 20 20.48 <0.05 1.14 >0.05 
 25 19.81 <0.05 1.57 >0.05 
 30 19.44 <0.05 2.56 >0.05 
D vs. R 5 7.44 <0.05 2.95 <0.05 
 10 11.63 <0.05 9.37 <0.05 
 15 5.26 <0.05 13.09 <0.05 
 20 0.37 >0.05 12.67 <0.05 
 25 1.28 >0.05 11.14 <0.05 
 30 1.99 >0.05 9.46 <0.05 
Almost all data obtained with USP paddle apparatus showed significant differences (*P<0.05). With flow-through cell method significant differences 
with data of generic formulations A and D were found (*P<0.05). 
 
Because variability of results was higher than that established for 
calculation of f2 similarity factor (CV ≤ 20% at first sampling time 
and ≤ 10% at other sampling time) [4], dissolution profiles were 
compared by model-independent and model-dependent methods. 
Model-independent comparisons 
Percentage of meloxicam dissolved at 30 min, as well as MDT and DE 
[mean±standard error medium (SEM)], of each formulation, are 
shown in table 5. 
 
Table 5: Dissolution parameters of meloxicam from reference (R) and generic formulations (A-D), mean±SEM, n = 12. *P<0.05 
Code Diss. at 30 min (%) MDT (min) DE (%) t50% (min) t63.2% (min) t85% (min) 
USP paddle apparatus 
R 86.15±0.54 10.50±0.12 56.00±0.47 10.75±0.20 15.49±0.24 27.18±0.35 
A 85.15±1.40 16.58±0.10* 38.12±0.84* 18.42±0.37* 23.28±0.46* 31.31±0.62* 
B 113.84±2.90* 9.70±0.18* 77.06±2.18* 6.61±0.36* 9.23±0.50* 15.02±0.83* 
C 105.56±0.34* 8.10±0.19* 77.05±0.51* 5.07±0.17* 7.54±0.22* 14.31±0.29* 
D 87.18±0.62 12.30±0.13* 51.45±0.65 13.05±0.32 17.55±0.37* 26.43±0.42 
Flow-through cell method 
R 76.11±1.86 14.84±0.22 38.36±0.66 19.24±0.37 24.63±0.50 33.89±0.85 
A 49.03±2.58* 23.51±1.17* 23.91±1.40* 36.07±2.22* 44.33±3.18* 57.64±5.01* 
B 84.25±3.57 15.33±0.28 41.42±2.29 18.07±0.96 22.95±1.19 31.11±1.55 
C 73.55±2.37 14.60±0.18 37.65±1.00 19.86±0.55 25.50±0.78 35.24±1.28 
D 85.56±1.04* 13.39±0.05 47.35±0.48* 15.05±0.17* 19.87±0.26 28.87±0.47 
 
With official dissolution test, model-independent parameters were 
ranked with respect to significant differences found as percentage of 
meloxicam dissolved at 30 min<DE<MDT. In the same way, for flow-
through cell method, parameters were ranked as MDT<DE = 
percentage of meloxicam dissolved at 30 min. 
Significant differences with percentage dissolved at 30 min were found 
with generic products B and C (using USP paddle apparatus) and with 
products A and D (using flow-through cell method). Comparing 
dissolution performance of generic drug products with MDT data, 
significant differences were found with all generic formulations using 
USP Apparatus 2 (*P<0.05) whereas with flow-through cell method, 
significant differences were found only with generic formulation A 
(*P<0.05). With DE data as comparison parameter, significant 
differences were found with three generic drug products (A, B, and C) 
when USP paddle apparatus was used (p<0.05), while with USP 
Apparatus 4 only generic product A was different. 
Comparisons using percentage dissolved at 30 min (Q values) are 
important for quality control purposes since these values give a 
measure of dissolution extent reached by each formulation under 
the same experimental conditions. MDT and DE were calculated 
because they have been proposed as acceptable parameters for in 
vitro/in vivo correlations levels B and C [27]. In vitro/in vivo 
correlation level B is established by the relationship between MDT 
and mean residence time (both parameters calculated by statistical 
moments theory), whereas in vitro/in vivo correlation level C uses 
the association of DE or another parameter as a dissolution time 
point (t50%, t80%, etc.) with one pharmacokinetic parameter, such as 
AUC, Cmax or Tmax. Previous reports suggest DE as a suitable 
parameter that reflects global drug dissolution behavior to compare 
dissolution profiles [21]. 
Model-dependent comparisons 
After adjustment of dissolution data to hyperbole equation t50%, 
t63.2%, and t85% values were calculated. Results are shown in table 
5. These time data reflect meloxicam dissolution rate differences 
showed by all drug products used under the same experimental 
conditions. With USP paddle apparatus, model-dependent 
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parameters were ranked respect significant differences as t50% = 
t85%<t63.2%. In the same way, for flow-through cell method, 
parameters were ranked as t63.2% = t85%<t50%. Comparing 
dissolution profiles of meloxicam drug products by these time 
data, when USP paddle apparatus was used, almost all generic 
formulations were different to the reference product; but when 
flow-through cell method was used, only one or two generic 
formulations were different to the reference product. In 
dissolution studies, it is common to calculate this time data since 
tx% corresponds to time required to release a certain percentage 
of drug (e. g., t20%, t50%, t90%) and sampling time corresponds to 
the amount of drug dissolved in that time (e. g., t20 min, t50 min, t90 
min). Pharmacopeias often use this time parameter as an 
acceptance limit of dissolution test (e. g., t45 min ≥ 80%) [5]. In 
order to find a relationship between model-independent and-
dependent data, MDT and t63.2% values of each USP apparatus 
were plotted, then a lineal regression was calculated. Results are 
shown in fig. 3. 
 
 
Fig. 3: Relationship between MDT and t63.2% of meloxicam from reference (R) and generic formulations (A-D), mean, n = 12 
 
In this dissolution performance study, time to dissolve 63.2% of 
meloxicam dose was calculated by different methodology. USP paddle 
apparatus gives more dispersed results meanwhile better results were 
found with flow-through cell method. Linear regression equation with 
USP paddle apparatus data was y = 1.87x–6.84 and with USP 
Apparatus 4 data was y = 2.34x–10.80. Although significant linear 
regression was found with both dissolution equipment (*P<0.05) a 
high R2 value was found only with the flow-through cell method. 
The trend presented by data of flow-through cell method, when 
using dissolution results of all meloxicam formulations, can be 
explained by the mathematical equation y = bx+a. USP Apparatus 4 
generates more stable hydrodynamic conditions than USP paddle 
apparatus and this advantage can help to better design dissolution 
tests to accurately reveal the quality of commercial formulations. 
Results agree with those found with naproxen generic tablets [28] 
and ibuprofen generic suspensions [29] where model-independent 
and-dependent parameters obtained with data generated by USP 
Apparatuses 2 and 4 were associated and flow-through cell method 
showed better adjustments. 
For a complete comparison of dissolution profiles by model-
dependent approach data of all meloxicam, formulations were fitted 
to different mathematical equations. Results are shown in table 6. 
 
Table 6: Criteria used to select the best-fit model, mean, n = 12 
Code First-order Higuchi Korsmeyer-peppas Hixson-crowell Makoid-banakar Weibull Logistic 
R2adjusted 
USP paddle apparatus 
R 0.9805 0.9205 0.9334 0.9750 0.9938 0.9997 0.9989 
A 0.8284 0.6836 0.9853 0.8723 0.9963 0.9984 0.9870 
B 0.7977 0.9070 0.9016 0.8827 0.9897 0.9997 0.8506 
C 0.9626 0.9006 0.9605 0.9708 0.9977 0.9997 0.9235 
D 0.9325 0.8483 0.9411 0.9661 0.9980 0.9988 0.9965 
Flow-through cell method 
R 0.9288 0.7869 0.9871 0.9573 0.9986 0.9999 0.9938 
A 0.8094 0.5761 0.9991 0.8296 0.9996 0.9991 0.9958 
B 0.8910 0.7637 0.9879 0.9309 0.9987 0.9993 0.9827 
C 0.9399 0.7973 0.9872 0.9656 0.9990 0.9999 0.9945 
D 0.9376 0.8347 0.9664 0.9693 0.9956 0.9993 0.9961 
AIC 
USP paddle apparatus 
R 25.55 34.55 34.25 27.41 19.77 -1.51 6.80 
A 42.34 46.03 27.92 40.56 18.51 13.33 27.04 
B 42.34 38.57 39.62 38.42 26.10 1.76 38.22 
C 28.38 33.44 29.45 26.83 12.22 -4.25 33.50 
D 35.58 40.57 35.43 31.20 13.92 10.40 17.82 
Flow-through cell method 
R 33.99 41.12 24.47 30.62 11.01 -9.63 17.49 
A 36.28 41.12 1.96 35.61 -3.36 -2.37 11.96 
B 38.25 43.06 24.19 35.39 11.02 -0.11 25.47 
C 32.43 40.30 23.95 28.89 8.68 -16.12 15.28 
D 34.83 40.77 31.83 30.55 19.86 8.30 18.06 
R: reference. A-D: generic formulations. AIC: Akaike Information Criterion. 
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Considering established criteria to choose the best-fit model 
(highest R2adjusted and lowest AIC value) all data generated by both 
USP dissolution apparatuses adjusted to Weibull equation, excepting 
generic formulation A with flow-through cell method, that adjusted 
to Makoid-Banakar equation. As almost all meloxicam dissolution 
data adjusted to the Weibull model, parameters derived to this 
adjustment (α, β, Ti, and Fmax) were used to calculate t50%. Results are 
shown in table 7. 
 
Table 7: Weibull parameters and t50% values (min) derived from data adjustment to this mathematical model, mean, n = 12 
Code α β Ti Fmax t50% (±SEM) 
USP paddle apparatus 
R 9.11 0.93 2.50 94.29 10.26±0.16 
A 45608.45 2.89 -5.24 96.26 18.81±0.29* 
B 7.69 0.95 2.68 119.13 7.08±0.30* 
C 4.70 0.69 1.45 118.90 5.21±0.16* 
D 180.00 1.80 -0.68 90.39 12.70±0.26* 
Flow-through cell method 
R 57.81 1.06 2.54 181.00 18.72±0.35 
B 535.21 1.19 2.09 882.36 17.77±0.98 
C 48.81 1.08 2.30 142.80 19.25±0.54 
D 19.20 1.00 3.04 113.89 14.23±0.15* 
 
With USP paddle apparatus significant differences were found for 
t50% values of all generic formulations (*P<0.05) meaning that 
dissolution profiles of meloxicam from these drug products were not 
similar to dissolution profile of reference formulation. With flow-
through cell method, significant differences were found only with 
generic product D (*P<0.05). 
Data fitting to mathematical equations described above was carried 
out without any physiological significance to find a model that 
explains the in vitro dissolution performance of meloxicam 
formulations. The purpose of using mathematical models to adjust 
dissolution profiles is that they facilitate the analysis and 
interpretation of results because they describe the dissolution 
profiles as a function of only a few parameters that can be 
statistically compared [30]. Silva Oliveira et al., [2] found the first-
order kinetic model more appropriate to explain dissolution data of 
three meloxicam commercial formulations (they used only zero-
order and first-order models). Significant differences were found 
between generic and reference formulations when comparing t50% 
data derived from the adjustment to this kinetic model. 
Similar results to those found in this work were reported by Medina 
et al., [28] where dissolution profiles of five generic formulations of 
naproxen sodium, obtained with USP Apparatuses 2 and 4, were 
compared with the reference formulation by model-dependent and-
independent approaches. With USP paddle apparatus, all generic 
formulations were different to reference product while with USP 
Apparatus 4 only two drug products were different to reference. 
In general, the comparisons made above indicate that when using 
USP paddle apparatus all dissolution profiles of generic formulations 
are different from dissolution profile of reference product while 
when using the flow-through cell method only one generic product 
shows a dissolution profile totally different to the profile of 
reference. This is relevant when considering that generic 
formulations must have a biopharmaceutical quality such as the 
reference product has in order to maintain the same safety and 
efficacy and authorize their commercialization. Laboratories that 
manufacture generic formulations, in extreme cases, must 
reformulate their product to equalize the dissolution process to that 
presented by reference, so before making this decision it is 
necessary to consider different dissolution schemes and choose the 
most adequate to not change the formulation due to a dissolution 
method that does not adequately reflect the dissolution performance 
of the products under study. 
Several authors reported that development of a dissolution 
procedure involves selecting the dissolution tester, media, apparatus 
type and hydrodynamic (agitation rate) appropriate for the product 
[17]. An alternative to evaluate drug dissolution is the flow-through 
cell method. Their advantages over conventional basket and paddle 
apparatus are widely demonstrated especially in dissolution of 
poorly soluble drugs in immediate-release dosage forms [24, 25, 31] 
and in modified-release dosage forms [32]. As USP Apparatus 4 best 
simulates hydrodynamic conditions of gastrointestinal tract it is 
important to investigate the applicability of flow-through cell 
method on the study of in vitro release of meloxicam generic 
formulations to develop dissolution methods with high 
discriminative capacity. 
A previous study with diclofenac sodium generic formulations 
shows that release characteristics vary considerably among different 
manufacturers and that even identical formulations showed rather 
dissimilar release profiles, therefore the interchangeability of the 
drugs used in that study is questioned [33]. Other authors reported 
that many potential factors can explain the differences between the 
branded and their generic counterparts [17]. Those included the 
manufacturer, apparatus type, surface area of a drug, surfactants, 
storage, dosage form and the level and type of excipients. 
Always in vitro/in vivo correlations are required to confirm differences 
in dissolution performance of generic formulations. The choice of the 
hydrodynamic environment under which the drug release is evaluated 
is a key factor in finding significant in vitro/in vivo correlation. Results 
suggest that manufacturers seeking significant in vitro/in vivo 
correlation with meloxicam formulations it is more advisable to look 
for it with flow-through cell method instead of USP paddle apparatus. 
Better results can be obtained with flow-through cell method since 
formulations may not be the problem. 
Owing to the lack of similarity between the release performance of 
some meloxicam generic products used in this study, it is necessary 
to conduct correlation studies to verify whether the in vitro 
differences are reflected in vivo before considering being safely 
interchangeable with the reference drug product. 
CONCLUSION 
This dissolution performance study reveals the need to look for better 
in vitro dissolution schemes for meloxicam tablets since USP paddle 
apparatus may not reflect properly the dissolution performance of 
meloxicam generic formulations and reference. It is suggested to 
evaluate in vivo performance of meloxicam formulations to confirm the 
predictability of this in vitro proposed methodology. 
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